Are Peptides Safe? What the Evidence Actually Shows

There is no single answer to whether peptides are safe, because “peptide” describes a chemical structure, not a type of product. A peptide is a short chain of amino acids. The word covers insulin, which millions of people with diabetes rely on; GLP-1 medicines such as semaglutide; bone-building drugs such as teriparatide; ingredients in cosmetic creams; collagen fragments sold as food; and unapproved compounds such as BPC-157 that have never completed a human safety trial. Asking whether “peptides” are safe is a little like asking whether “chemicals” are safe.

A more useful approach is to ask four separate questions:

• Which molecule? Each peptide acts on its own targets in the body and has its own pattern of wanted and unwanted effects.
• Is it an approved medicine with human trial data? Approval means a regulator has weighed the evidence on benefits and risks for a stated use.
• What is the product quality? The same molecule can be made to pharmaceutical standards or in a poorly controlled process, and that changes the risk.
• Who is using it, and for what? Age, pregnancy, other illnesses and other medicines all change the balance.

Even for approved medicines, “safe” does not mean free of risk. The U.S. Food and Drug Administration (FDA) explains that all medicines have risks as well as benefits, and that when a medicine’s benefits outweigh its known risks, the FDA considers it safe enough to approve [1]. For a fuller explanation, see What FDA Approval Means and Approved vs Unapproved Peptides.

Yes, peptides can have side effects, and for approved peptide medicines those side effects are documented in detail. Large randomised trials, which compare a medicine with a placebo or another treatment, are designed partly to measure how often unwanted effects happen. The results appear in the official product label, also called the prescribing information, which for semaglutide includes tables of adverse reactions seen in trials [2].

GLP-1 receptor agonists. The most common side effects of this class are digestive. In the STEP 1 trial of semaglutide for weight management, which randomised 1,961 adults, nausea and diarrhoea were the most common adverse events; they were typically mild to moderate, temporary and subsided with time. More people stopped treatment because of digestive effects in the semaglutide group (4.5%) than in the placebo group (0.8%) [3]. A pooled analysis of 16 trials in type 2 diabetes reported digestive disorders in 41.9% of people on injected semaglutide and 39.1% on oral semaglutide, against 22.0% and 24.8% on comparison treatments [4]. The current Wegovy label also lists less common but more serious risks, including acute pancreatitis and gallbladder disease [2].

Insulin. The main known risk of insulin is hypoglycaemia, meaning blood glucose that falls too low. How often it happens depends heavily on the type and duration of diabetes. In a UK observational study, severe hypoglycaemia occurred about 0.2 times per person per year in people with type 2 diabetes who had been using insulin for less than two years, compared with about 1.1 times per person per year in people with type 1 diabetes of under five years’ duration and 3.2 times in those with type 1 diabetes for more than 15 years [5].

These examples show the general pattern for approved medicines: side effects are expected, they are measured and their frequency is known well enough to be written down, monitored and discussed with a prescriber. They are specific to each medicine and should not be assumed to apply to every peptide. For an overview of which peptide drugs are approved, see Approved Peptide Medicines and FDA-Approved Peptides.

For unapproved peptides the central problem is different: there is usually too little human evidence to say how safe or unsafe they are. In July 2026 the FDA published detailed briefing documents for an advisory committee that reviewed several popular peptides for possible use in pharmacy compounding.

• BPC-157. The FDA concluded that there is insufficient clinical safety information to characterise the safety profile of BPC-157. It found no carcinogenicity studies, which are animal studies designed to detect cancer risk. Short studies of repeated injections in rats and dogs suggested possible effects on blood clotting and liver markers, and longer studies were unavailable [6]. A 2025 systematic review of BPC-157 in sports medicine included 36 studies, of which 35 were preclinical (in cells or animals) and one was clinical, and found no clinical safety data [7].
• TB-500. The FDA said it had not identified any clinical studies or human exposure data for TB-500 by any route, and that potential safety risks in humans are therefore unknown [8].
• Other peptides. The FDA’s list of bulk substances that may present significant safety risks in compounding notes potential immune reactions for several peptides and, for some, a lack of any human exposure data [9].

A lack of reported harm is not evidence of safety. Small studies can easily miss uncommon side effects, and the FDA notes that pharmacies compounding under section 503A generally do not report adverse events to it [6]. Some unapproved peptides do have documented serious harms: for Melanotan II, the FDA cites published case reports of melanoma, a brain-swelling syndrome called posterior reversible encephalopathy syndrome, a toxic overstimulation of the nervous system and priapism [9]. One published case describes a man admitted to intensive care with muscle breakdown (rhabdomyolysis) and kidney impairment after injecting Melanotan II obtained online [10].

Reporting suspected side effects. Because so little trial data exist, reports from patients and clinicians are one of the few ways regulators learn about harm. In the United States, suspected problems can be reported to the FDA’s MedWatch programme [11]; in the UK, to the MHRA Yellow Card scheme [12]. A report is a signal to investigate, not proof that a product caused the problem. For more detail, see Peptide Side Effects: What Users Report and What the Evidence Shows and Human vs Preclinical Research.

A peptide’s safety depends not only on the molecule but on the product in the vial. Approved medicines are manufactured and tested under regulatory controls. Products sold online outside those controls may contain the wrong amount of the substance, unwanted by-products or bacterial contamination.

A 2024 study tested semaglutide products obtained from illegal online pharmacies without a prescription. All three vials that arrived were judged probably substandard or falsified: measured purity was between 7.7% and 14.37%, the semaglutide content was 28.56% to 38.69% higher than labelled, and one vial had a raised level of bacterial endotoxin (a fever-causing toxin from bacterial cell walls); the detailed results report the other two only as below a measurement limit. None of the three prefilled pens ordered was ever delivered [13].

Impurities matter for a second reason: they can provoke unwanted immune reactions, known as immunogenicity. A 2023 review explains that new impurities in peptide products may introduce sequences that the immune system recognises as foreign, which is why regulators ask manufacturers of generic peptide medicines to characterise them [14]. The FDA concluded that BPC-157 may pose a significant risk for immunogenicity, potentially amplified by aggregation (peptide molecules clumping together) and peptide-related impurities [6].

Errors in handling can also cause harm. The FDA has received reports of adverse events, some requiring hospitalisation, linked to errors in measuring and administering compounded semaglutide injections drawn from multi-use vials [15]. For practical background, see Peptide Impurities, Immunogenicity, Certificates of Analysis and Compounded Peptides.

Concern about cancer comes up often, and it helps to separate three kinds of evidence: a theoretical concern, a finding in animals and a demonstrated effect in people. Many peptides act on growth, cell movement or blood-vessel formation, which is why the question is reasonable. But a plausible mechanism is not the same as a proven risk.

Animal findings that did not translate. Teriparatide, a fragment of human parathyroid hormone used for osteoporosis, caused osteosarcoma (a bone cancer) in rats exposed to high levels of the drug for most of their lives. It was approved in the United States with a boxed warning. A 15-year US surveillance study then found that osteosarcoma in teriparatide users occurred at about the rate expected in the general population (standardised incidence ratio 0.72) [16]. On the strength of this and other real-world evidence, the boxed warning was removed in 2020 [17].

Animal findings of unknown relevance. The Wegovy label carries a boxed warning that semaglutide causes thyroid C-cell tumours in rodents, and states that it is unknown whether it causes such tumours, including medullary thyroid carcinoma, in humans. The medicine must not be used by people with a personal or family history of that cancer or of multiple endocrine neoplasia type 2, an inherited tumour syndrome [2].

Unanswered questions. For many unapproved peptides the question has simply not been tested. The FDA found no carcinogenicity studies for BPC-157, while noting that researchers have suggested its apparent effects may involve promoting blood-vessel growth [6]. Untested is not the same as safe, and it is not the same as dangerous. For Melanotan II, published case reports of melanoma exist, although case reports cannot establish cause [9].

Are peptide injections safe? Injection is a route of delivery, not a risk level in itself. Many approved peptide medicines are injected because digestive enzymes would break them down if swallowed. An approved injectable is manufactured to be sterile and comes with instructions and warnings; the Wegovy label, for example, warns that a pen must never be shared between patients, even if the needle is changed [2]. The added risks of injection arise mainly when the product is not made to pharmaceutical standards, as with the endotoxin found in online semaglutide vials [13], or when it is measured or handled incorrectly [15].

Are oral peptides safe? Most peptides taken by mouth are digested before they can reach the bloodstream, which is why few peptide medicines are tablets (see Peptide Bioavailability). Where an oral form has been approved, its safety has been studied directly. Oral semaglutide, for instance, showed a digestive side-effect profile similar to the injected form in pooled trial data [4]. Swallowing a peptide is therefore neither automatically safer nor automatically harmless. Collagen and other peptides sold as foods or supplements belong to a different regulatory category from medicines; see Peptide Supplements vs Peptide Medicines.

Are synthetic peptides safe? “Synthetic” describes how a peptide is made, not whether it is safe. Many approved peptide medicines are made by chemical synthesis or in engineered cells. What matters is the evidence on the specific molecule and the quality of the specific product. The same applies in reverse: a peptide described as “natural” or “bioidentical” is not proven safe by that label. See Natural vs Synthetic Peptides.

Safety evidence is thinnest for the groups many people worry about most. Pregnant women have historically been left out of most clinical trials; the FDA has published draft guidance on how they might be included more carefully, so that information on medicine use in pregnancy can be gathered [18].

Approved medicines have dedicated sections in their labels on pregnancy, breastfeeding and use in children. The Wegovy label, for example, states that animal studies suggest possible risks to the fetus, that available human data are insufficient to establish a drug-associated risk, and that a pregnancy exposure registry is monitoring outcomes [2]. Some peptide medicines have been tested in adolescents. In the STEP TEENS trial, 201 young people aged 12 to under 18, nearly all with obesity, were randomised to semaglutide or placebo; digestive side effects occurred in 62% versus 42%, and gallstones in five participants on semaglutide versus none on placebo [19]. On the basis of that trial, the label states that safety and effectiveness for that specific use have been established in patients aged 12 and older [2].

Unapproved peptides generally have no human data at all in pregnancy, breastfeeding or adolescence. For these groups the honest answer is that the risks are unknown. Anyone who is pregnant, breastfeeding, planning a pregnancy or under 18, or who is caring for someone in those groups, should discuss any peptide product with a doctor, midwife or pharmacist. This guide does not give individual medical advice. Athletes face additional rules; see Peptides and Athletes.

Are peptides safe to take?

It depends on the peptide and the product. Approved peptide medicines have known side-effect profiles and are considered safe enough to use when their benefits outweigh their known risks for an approved purpose [1]. Many unapproved peptides sold online lack the human data needed to judge their safety [6] [8].

Are peptides safe for teenagers?

Only approved medicines have been tested in teenagers, and only for specific conditions; semaglutide, for example, was studied in adolescents with obesity in the STEP TEENS trial [19]. Peptides promoted online for muscle, looks or tanning have no safety data in people under 18, and growth, puberty and hormone development make that age group a special case. Anyone under 18 should talk to a doctor before using any peptide product.

Can peptides cause cancer?

Some peptide medicines carry warnings based on animal findings, such as thyroid C-cell tumours in rodents with semaglutide, whose relevance to humans is not known [2]. In the case of teriparatide, a rat finding was not borne out by 15 years of human surveillance [16] [17]. Many unapproved peptides have never been tested for cancer risk [6].

Do peptides have side effects?

Yes. Every active medicine can have side effects. For GLP-1 medicines the most common are digestive, such as nausea and diarrhoea [3] [4]; for insulin the main risk is low blood glucose [5].

Are peptide injections safe?

Approved injectable peptides are made sterile and are used with specific instructions and warnings [2]. Products made outside pharmaceutical controls can carry contamination such as bacterial endotoxin [13].

Are peptides safe during pregnancy, breastfeeding or for teenagers?

These groups are rarely studied. Approved medicines have specific label sections for them [2]; unapproved peptides generally have no data. Talk to a clinician before using any peptide product in these situations.

Are oral or synthetic peptides safer?

Not automatically. The route and the manufacturing method do not determine safety on their own; the evidence for the specific molecule and the quality of the specific product do [4]. For a broader overview of risk types, see Are Peptides Safe? Understanding Different Types of Risk.